CTNNB1 and neoplasm: Notably, in patient 5, a tumor rebiopsy revealed a significant increase in CTNNB1 mutation frequency (0.4%-30.0%), alongside an increase in EGFR allele frequency (27/28% to 62/62%), correlating with a higher tumor cell content (40% v 70% at rebiopsy).